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Background: The small molecule NSC676914A was previously identified as an NF-κB inhibitor in TPA-stimulated
HEK293 cells (Mol Can Ther 8:571-581, 2009). We hypothesized that this effect would also be seen in ovarian cancer
cells, and serve as its mechanism of cytotoxicity. OVCAR3 and HEK293 cell lines stably containing a NF-κB luciferase
reporter gene were generated.
Methods: Levels of NF-κB activity were assessed by luciferase reporter assays, after stimulation with LPA, LPS, TPA,
and TNFα, in the presence or absence of a known NF-κB inhibitor or NSC676914A, and cytotoxicity was measured.
Results: NSC676914A was toxic to both OVCAR3 and HEK293 cells. We also investigated the cytotoxicity of
NSC676914A on a panel of lymphoma cell lines with well characterized mutations previously shown to determine
sensitivity or resistance to NF-κB inhibition. The compound did not show predicted patterns of effects on NF-κB
activity in either lymphoma, ovarian or HEK293 cell lines. In HEK293 cells, the small molecule inhibited NF-κB when
cells were stimulated, while in OVCAR3 cells it only partially inhibited NF-κB. Interestingly, we observed rescue of cell
death with ROS inhibition.
Conclusions: The current study suggests that the effect of NSC676914A on NF-κB depends on cell type and the
manner in which the pathway is stimulated. Furthermore, as it is similarly toxic to lymphoma, OVCAR3 and HEK293
cells, NSC676914A shows promising NF-κB-independent anti-cancer activity in ovarian tumor cells.
Keywords: Ovarian cancer, NF-κB, IKKβ, NSC676914, ChemotherapyBackground
Ovarian cancer is frequently diagnosed in the late stages
of the disease, and is the most common cause of death
among gynecological cancers in women in the United
States. Moreover, even as it only accounts for 3% of can-
cer cases in women, it is the fifth most common cause
of death from all cancers [1]. The NF-κB family of gene
transcription factors plays an important role in cell sur-
vival and proliferation, and constitutive NF-κB signaling
has been identified in tumors of epithelial origin. Recent
evidence suggests that this pathway also plays a role in* Correspondence: annunzic@mail.nih.gov
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unless otherwise stated.ovarian cancer; NF-κB activation has been shown to in-
crease the aggressiveness of ovarian cancer cell lines [2],
and overexpression of the NF-κB subunit p50 has been
shown to be positively correlated with poor outcome
among ovarian cancer patients [3]. NF-κB signaling is
therefore a potential target for therapeutic treatment of
this disease.
Platinum-based and taxane-based chemotherapy are
staples in the treatment of ovarian cancer. Even so, the
relapse rates for ovarian cancer patients are extremely
high [4], which emphasizes the importance of exploring
new therapeutic agents. NSC676914 was recently identi-
fied as an NF-κB inhibitor in a high-throughput screen
of a synthetic library aimed at identifying AP-1 inhibi-
tors [5], and shown to inhibit NF-κB transcriptional ac-
tivity at low concentrations in TPA-stimulated HEK293Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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For the work we present in this manuscript, we purified
an active component, here designated NSC676914A, and
determined the structure (Additional file 1: Figure S1A).
The material used in this study is newly synthesized pure
NSC676914A. In this study we hypothesized that this
small molecule could be selectively toxic to ovarian cancer
cells that rely on NF-κB signaling for proliferation and sur-
vival. We discovered, however, a broader applicability of
this compound across cancers, with reasonable activity
against ovarian cancer cell lines.
Results
In a previous study [4] using HEK293 cells, NSC676914A
was shown to inhibit NF-κB activity in vitro at low micro-
molar concentrations in a dose-dependent manner. A puri-
fied version of the compound was recently synthesized,
and submitted to the NCI-60 tumor cell panel for growth
inhibition analysis (Figure 1A). Results showed an overall
tumor cell median GI50 of −5.91, with greater sensitivities
found in the leukemia, melanoma, colon and ovarian can-
cer cell groups (Figure 1B, Additional file 2: Table S1).
Within the ovarian cancer cell panel, NSC676914A caused
50% or more growth inhibition of 7 ovarian cell lines at
concentrations between 1 and 10 μM, the same concentra-
tion at which NF-κB was inhibited in HEK293 cells [5].
BAY-7085 (NSC663627) is a known inhibitor of NF-
κB, and we sought to determine whether its pattern of
toxicity resembled that of NSC676914A. This compound
resulted in only mild toxicity to the ovarian cancer cell
lines in the NCI-60 panel (Additional file 3: Figure S2A).
A COMPARE analysis of BAY-7085 indentified a num-
ber of highly correlated compounds of known NF-κB in-
hibitory activity (Additional file 3: Figure S2A, B). This
analysis suggested a wide variation in patterns of toxicity
of compounds inhibiting NF-κB activity.
In order to clarify the mechanism of NSC676914A
toxicity in ovarian cancer cells, we assessed the sensitivity
of an expanded ovarian cancer cell panel and HEK293
cells to the compound at low micromolar concentrations.
NSC676914A caused 50% growth inhibition for all the cell
lines between the range of 0.5-1.25 μM. We also investi-
gated the effect of NSC676914A treatment on a panel of
lymphoma cell lines with well characterized mutations
previously shown to determine sensitivity or resistance to
NF-κB inhibition [6]. This panel of cell lines could demon-
strate the point at which a compound interferes with
NF-κB signaling, based on the pattern of sensitivity. The
IKKβ -dependent cell lines carry a mutation upstream of
IKKβ, that activates the kinase. The IKKβ -independent
lines do not depend on IKKβ activity for survival. As
shown in Figure 2B, upon treatment with IKKβ inhibitor,
sensitive lines presented significant growth inhibition at
0.5-2 micromolar concentrations, while resistant linesrequired at least 5–10 times the dose. NSC676914A was
equally toxic to all lymphoma cell lines (Figure 2C),
while its unsulfated alcohol analog was non-toxic to all
ovarian and lymphoma cell lines (Figure 2D). The
unsulfated alcohol analog (Additional file 1: Figure S1B)
was included as a control since previous studies showed
it to be inactive in inhibiting NF-κB in HEK293 cells.
Taken together, these data suggest that NSC676914A is
toxic to IKKβ-dependent and -independent lymphoma
lines, and therefore must act by a different mechanism.
We next sought to investigate the effect of NSC676914A
on NF-κB signaling in HEK293 cells. We measured NF-κB
transcriptional activity of HEK293 cells transiently trans-
fected with a luciferase reporter plasmid. Indeed, the com-
pound significantly inhibited NF-κB activity (72% and 61%
inhibition at 10 μM and 2 μM concentrations, respect-
ively) in TPA-stimulated cells after 18 h treatment, con-
firming earlier findings (Additional file 4: Figure S3A).
The published studies were performed with the unpurified
compound, and using transiently transfected HEK293
cells. In order to compare HEK293 cells and ovarian can-
cer cells, we established stable OVCAR3 and HEK293 cell
lines expressing a luciferase reporter gene responding to
an NF-κB transcriptional regulatory element. Under these
new conditions, the pure NSC676914A partially blocked
NF-κB activity induced by TNFα stimulation for 18 h in
OVCAR3, but was more effective in HEK293 cells
under stimulation with TPA (Figure 3A, B). The higher
concentrations of the impure compound were previously
shown to cause growth inhibition after 72 h exposure. In
our current study, IKKβ inhibition caused a 40-70% dose-
dependent decrease in HEK293 luciferase activity, while
pure NSC676914A produced a dose-dependent 95-98%
decrease. OVCAR3 cells, in turn, showed a 45-70% de-
crease in luciferase activity after IKKβ inhibition, however
NSC676914A produced only a 23-33% decrease, sugges-
ting that this compound is a much more potent NF-κB ac-
tivity inhibitor in TPA-stimulated HEK293 cells than in
TNFα-stimulated OVCAR3 cells.
Ovarian cancer cells respond to a number of different
physiological stimuli. We therefore investigated the NF-κB
inhibition achieved by NSC676914A in both OVCAR3
and HEK293 reporter lines, following stimulation by LPA,
LPS, TPA or TNFα in order to clarify whether the com-
pound had a greater effect in a particular pathway trigger-
ing NF-κB activation. We chose to use the concentration
of 1.25 μM, which achieves the maximum level of NF-κB
inhibition under stimulation with TNFα, and beyond which
there is no further inhibition (Figure 3A). NSC676914A
did not inhibit constitutive NF-κB signaling in OVCAR3
cells; HEK293 cells had very little constitutive NF-κB
activity (Additional file 4: Figure S3B). OVCAR3 cells
responded minimally to LPA and LPS stimulation, while
TPA and TNFα caused the greatest increase in NF-κB
Figure 1 NSC676914A shows differential toxicity to NCI-60 cancer lines. (A) Growth inhibition of NCI-60 cancer cell lines after exposure to
NSC676914A. NCI-60 cancer panel cells are plated for 24 h prior to addition of compound. Cells are then incubated for an additional 48 h and cell
number estimated by Sulforhodamine B staining as described. (B) GI50 is the calculated micromolar concentration resulting in 50% reduction in
the measured protein at the end of drug treatment compared to that at the beginning. The median log GI50 for NSC676914A over all cell lines
was −5.91.
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Figure 2 NSC676914A inhibits HEK293 and ovarian cancer cell proliferation. (A) Proliferation of HEK293 and a panel of ovarian cancer cell
lines after 72 h treatment with varying concentrations of NSC676914A. Cell viability was assessed by XTT assay as described and reported as
percent untreated control. Data are representative of 3 experiments. (B) Viability of 3 human lymphoma lines (open markers) sensitive to NFκB
inhibition, and 3 resistant lymphoma lines (closed markers) after 72 h treatment with IKKβ inhibitor. (C) Viability of ovarian cancer cell lines after
72 h exposure to NSC676914A. (D) Proliferation of the same panel of ovarian lines in (A), plus above described lymphoma lines after treatment
with the inactive NSC676914A unsulfated alcohol analog.
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erase activity in all cases by 50-70%, while NSC676914A
had minimal (4-30%) effects. Similarly, in HEK293 cells,
TNFα and TPA had the greatest ability to activate
NF-κB (Figure 3D). In these cells, however, NSC676914A
was more effective than IKKβ inhibitor in blocking NF-κB
activity after TPA stimulation (98% decrease). These data
suggest that NSC676914A has a cell-specific and pathway-
specific mechanism of inhibiting NF-κB activity. It is un-
clear, however, to what extent the inhibition of NF-κB is
the reason for the cytotoxicity seen.
In order to clarify whether the mechanism by which
NSC676914A is toxic in HEK293 cells is also responsible
for killing cancer cells, parental HEK293 and OVCAR3
cells were pre-treated with 3 specific inhibitors: Caspase-
mediated death (ZVAD), caspase-independent necroptosis
(NEC-1), and ROS-mediated death (NAC), prior to treat-
ment with NSC676914A or IKKβ inhibitor. OVCAR3
cells were treated in the presence or absence of TNFα.
NSC676914A is more toxic to unstimulated HEK293
and OVCAR3 cells than IKKβ inhibition (Figure 4A, B).
The ROS-inhibitor NAC completely rescued cell death
induced by NSC676914A, but ZVAD or NEC-1 were in-
effective, suggesting that cell death in unstimulated cellsdoes not proceed through an apoptotic or necroptotic
mechanism. However, TNFα-stimulated OVCAR3 cells
are killed by both NSC676914A and IKKβ inhibition
(Figure 4C). The cell death that follows TNFα and IKKβ
inhibition clearly involves a caspase-dependent cell
death that can be rescued by ZVAD, while NSC676914A
only induces a ROS-dependent cell death. ROS produc-
tion by NSC676914A was confirmed (Additional file 5:
Figure S4).
Discussion
Our data suggest that NF-κB activity in HEK293 cells is
inhibited by NSC676914A at low concentrations; however
this effect is not its primary mechanism of toxicity, as
IKKβ inhibition alone is less toxic to the cells. In addition,
in a well characterized panel of lymphoma cell lines,
NSC676914A was equally toxic to cell lines known to be
dependent or independent of IKKβ signaling, consistent
with the idea that NSC676914A kills cells by a mechanism
other than IKKβ inhibition. Further, in TNFα-stimulated
ovarian cancer cells this compound was equally toxic as
IKKβ inhibition; however the IKKβ inhibitor clearly
proceeded through a caspase-dependent mechanism
while NSC676914A did not. These findings suggest that
A B
C D
Figure 3 NSC676914A differentially affects NF-κB transcriptional activity. (A) NF-κB activity following 18 h treatment with varying concentrations
of NSC676914 and IKKβ inhibitor, during stimulation of OVCAR3 cells with TNFα (A) and HEK293 cells with TPA (B), as described. NF-κB activity
following 18 h treatment with varying concentrations of NSC676914A or IKKβ inhibitor, during stimulation of OVCAR3 cells (C) and HEK293 cells
(D) with 1 μM LPA, 1 μg/ml LPS, 10nM TPA and 10 ng/ml TNFα as described. Significant differences in treated OVCAR3 activity were compared
between cells with each stimulant and no inhibitors present, as indicated. * p < 0.01, **p < 0.001, ***p < 0.0001.
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to the signaling pathway triggered by TPA stimulation
in HEK293 cells, which is not the mechanism by which
it kills cells.
The NCI-60 panel of cell lines shows that NSC676914A
has some preference for ovarian cancer cell lines, among a
few other cell types. While its exact target remains un-
known, it displays broad toxicity to 10 ovarian cancer cell
lines, in our hands and the NCI-60 panel. This includes
the drug-resistant cell line, NCI/ADR-RES in the NCI-60
panel. There was the least amount of cell killing in the
lung cancer, kidney cancer and CNS cancer cell lines in
the NCI-60, suggesting that the drug is not broadly toxic
to growing cell lines, but displays some degree of specifi-
city to ovarian cancer. Interestingly, an earlier unpurified
version of NSC676914 was able to potentiate topotecan
killing of neuroblastoma cells [7].
Future work with the NSC676914A compound could in-
clude investigation into its specific targets within the cell,
its differential effects on NF-κB signaling in HEK293 cells
as opposed to OVCVAR3 cells, and its mechanism of
inducing cell death overall. We found that its cytotoxic
activity was not blocked by inhibitors of apoptosis ornecroptosis, but it was deactivated by pretreatment
with NAC, a scavenger of ROS. Many anti-cancer agents
increase reactive oxygen species as a means to kill can-
cer cells, thus making this a reasonable therapeutic
strategy [8].
Conclusions
NSC676914A shows promising anti-cancer activity in a
range of cell lines, including ovarian cancer, regardless
of their dependence on NF-κB signaling. Future studies
should further investigate its cellular target in order to
optimize its delivery in the clinical setting.
Methods
Reagents
NSC676914A (Additional file 1: Figure S1A) was synthe-
sized by diazotization of 2-[(4-aminophenyl)sulfonyl]-1-
hydrogen sulfate followed by coupling with m-toluidine.
An unsulfated alcohol analog (Additional file 1: Figure S1B)
was similarly prepared from 2-[(4-aminophenyl)sulfonyl]-
1-ethanol. Both compounds were purified to >95% pur-
ity by reverse phase HPLC. DMSO stocks were used
for all experiments. IKKβ inhibitor (IKK-2 Inhibitor IV
Figure 4 NSC676914A cytotoxicity is rescued by ROS inhibitor. Cell death in parental HEK293 and OVCAR3 cells after 3 days of exposure to
NSC676914A or IKKβ inhibitor. Viability of HEK293 cells (A) or OVCAR3 cells (B) and TNFα-treated OVCAR3 (C) cells, after 72 h exposure to
NSC676914A or IKKβ inhibitor, following 1 h pretreatment with cell death inhibitors ZVAD 10 μM, NEC-1 20 μM, NAC 1 mM, as described in
Methods. Data are average of three independent measurements.
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catalog #401484) (Additional file 1: Figure S1C) was
purchased from EMD Biosciences (La Jolla, CA). LPA
(857130C) was purchased from Avanti Polar Lipids
(Alabaster, AL). LPA stocks were made in PBS containing
1% fatty acid-free bovine serum albumin. TPA (4174) was
purchased from Cell Signaling Technology, Inc (Danvers,
MA). Recombinant Human TNFα (300-01A) was pur-
chased from Peprotech (Rocky Hill, NJ). Z-VAD-FMK
(2163) and Necrostatin-1 (2324) were purchased from
Tocris Bioscience (Ellisville, MO). Puromycin, XTT, PMS,
LPS (L5293) and N-Acetyl-L-cysteine (A7250) were pur-
chased from Sigma-Aldrich (St. Louis, MO).
Cell lines and culture conditions
Ovarian cancer cell line OVCAR3 was a gift from Elise
Kohn (NCI, Bethesda, MD), HEYA8 was a gift from
Gordon Mills (MD Anderson Cancer Center, Houston,
TX), and 1A9 cells were a gift from A.T. Fojo (NCI,
Bethesda, MD); OVCAR5, OVCAR8, and IGROV1 cells
were from the NCI-Frederick Developmental Therapeu-
tics Program tumor/cell line repository (Frederick, MD).
Human embryonic kidney (HEK293) MDAH2744 and
CAOV3 cells were obtained from ATCC. Lymphoma cell
lines Ly10, HBL1, Ly3, Ly8, BJAB and Ly8 were a gift from
L. Staudt (NCI, Bethesda, MD). Ovarian and lymphoma
cancer cell lines were cultured in RPMI 1640, HEK293
was cultured in DMEM, all containing 10% fetal bovine
serum (Hyclone, Pittsburgh, PA) and standard antibiotics.
All media were obtained from Invitrogen (Carlsbad, CA).
Cell lines were authenticated in July 2009 at the Johns
Hopkins University Fragment Analysis Facility (Baltimore,
MD), using Promega PowerPlex 1.2 System to test for
8 STR markers (D16S539, D7S820, D13S317, D5S818,
CSF1PO, TPOX, THO1, vWA) and amelogenin for gen-
der determination. Authenticity was confirmed against
the ATCC database www.atcc.org/CulturesandProducts/
CellBiology/STRProfileDatabase/tabid/174/Default.aspx)
CLIMA database (http://drcat.sourceforge.net/clima.html)
and NCI-60 database published data [9].
NCI-60 tumor cell panel
Cytotoxicity screen of NSC676914A was performed by the
Developmental Therapeutics Program of NCI (NIH), as
described (http://dtp.nci.nih.gov). The synthesized com-
pound was submitted for testing in the NCI-60 panel on
February 25, 2013. COMPARE analysis was performed
through the DTP website as described [10].
Luciferase reporter assays
HEK293 cells transiently transfected as described with an
NF-κB reporter [5] were treated with NSC676914A or
an alcohol analog lacking the sulfate group, previously
shown to be inactive in HEK293 cells. After TPAtreatment, NF-κB activity was measured using the Luciferase
Assay System as per manufacturer’s instructions. OVCAR3
and HEK293 cell lines were transduced with a lentiviral
construct containing an NF-κB reporter gene (CLS-013 L),
which was obtained from SABiosciences (Frederick, MD),
according to the manufacturer’s specifications. At the con-
clusion of the transduction, successfully transduced cells
were selected using 1 μg/ml puromycin for two weeks, and
stable cell lines were maintained. The Luciferase Assay
System (E1501) was purchased from Promega (Madison,
WI) to measure NFκB activity, which was done following
the manufacturer’s protocol. In brief, cells were seeded
at a density of 10,000 cells/well in 96-well plates for
24 hours, and then serum-starved with 0.5% FBS for
24 hours. From concentrated stocks, NFκB inhibitors
(0–2.5 μM) were added, followed by varying concen-
trations of stimulants LPA (1 μM), TPA (10 nM), LPS
(1 μg/ml) and TNFα (10 ng/ml) one hour later. After
18 hours of incubation, cells were washed with PBS,
lysed and Luciferase Assay Reagent (LAR) added. Lumines-
cence was measured in a Molecular Devices (Sunnyvale,
CA) SpectraMax M5 Multi-Mode Microplate Reader using
the Dual-Luciferase_SpectraMax L protocol. Data were
normalized to cell number measured by XTT cell viabil-
ity assay [11] in duplicate plates.Cell viability assays
Attached cell growth was assessed using XTT as described
[11]. Cells were seeded in 96-well plates at a density of
2,000-5,000 cells/100 μl/well and incubated for up to
72 hours after NSC676914A (0–2.5 μM) was added. In
experiments using cell death inhibitors, CellTiter-Glo Lu-
minescent Cell Viability Assay (G7571) was purchased
from Promega (Madison, WI) and performed following the
manufacturer’s protocol. In brief, cells were pretreated with
the pan-caspase inhibitor Z-VAD-FMK (ZVAD, 10 μM),
necroptosis inhibitor Necrostatin 1 (NEC-1, 20 μM), or
ROS inhibitor N-Acetyl-L-cysteine (NAC, 1 mM) for one
hour. In OVCAR3 cells medium was supplemented with
10 ug/ml TNFα. NSC676914A or IKKβ Inhibitor was then
added at 1.25 μM, and all cultures incubated for 72 hours
before measuring luminescence with a Molecular Devices
SpectraMax M5 Multi-Mode Microplate Reader, using the
CellTiter-Glo_SpectraMax L protocol.Statistical analyses
Experiments were conducted using 6 replicates of each ex-
perimental condition. Results were analyzed for significant
differences using two-tailed T-tests in Microsoft Excel.Reactive oxygen species detection assays
Please see Additional file 6.
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Additional file 1: Figure S1. Chemical structures of compounds used in
the study. (A) NSC676914A, (B) the unsulfated alcohol analog, (C) the
commercially obtained specific IKKβ inhibitor [5-(p-Fluorophenyl)-2-ureido]
thiophene-3-carboxamide.
Additional file 2: Table S1. GI50 values for NSC676914A cytotoxicity in
NCI-60 cell panel.
Additional file 3: Figure S2. NCI-60 cell growth inhibition pattern of
NF-κB inhibitors. (A) Growth inhibition of NCI-60 cancer cell lines after
exposure to NF-κB inhibitor BAY 11-7085 and others. NCI-60 cancer panel
cells are plated for 24 h prior to addition of compound. Cells are then
incubated for an additional 48 h and cell number estimated by
Sulforhodamine B staining as described. (B) COMPARE analysis of toxicity
correlations between other inhibitors and BAY 11-7085 performed
through DTP website as described.
Additional file 4: Figure S3. NF-κB reporter activity with analogs of
NSC676914A. (A) HEK 293 cells were transiently transfected with an
NF-κB luciferase reporter construct and helper constructs as described in
Methods. Cells were pretreated with the indicated concentrations of
compounds for 1hour and stimulated with 10 nM TPA for 18 h; luciferase
reporter activity was measured as described, and calculated as percent of
control. (B) NF-κB signaling in OVCAR3 and HEK293 cells stably expressing
reporter vector under no stimulation, as described in Methods. NSC676914A
had no effect on constitutive NF-κB activity.
Additional file 5: Figure S4. Reactive Oxygen Species (ROS) Levels in
OVCAR3 cells after treatment with NSC676914A. DCFDA levels measured
after 2 hours after treatment of OVCAR3 cells with known inducer of ROS
400 μM H2O2 (positive control), and 1.25 μM NSC676914A, as described
in Additional file 6. NSC676914A produces an increase in ROS in OVCAR3 cells.
Additional file 6: Reactive oxygen species detection assays.
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